Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.75 |
| ▸ | EGFR | P00533 | 15/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.75 |
| ▸ | FLT1 | P17948 | 14/20 | 0.75 |
| ▸ | FLT4 | P35916 | 12/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | TEK | Q02763 | 2/20 | 0.63 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426435 | 0.93 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5428286 | 0.93 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5428279 | 0.93 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5428945 | 0.93 | FLT1 (0.77) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5428610 | 0.92 | EGFR (0.77) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5432127 | 0.92 | KDR (0.77) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5425844 | 0.91 | EGFR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5428039 | 0.90 | KDR (0.73) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5429132 | 0.89 | KDR (0.72) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5430025 | 0.88 | KDR (0.70) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653965-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | Astrazeneca AB (SE) | 2006-05-10 | — | — | EP | claimed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | claimed |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| EP-1653965-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | Astrazeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | FLT4, FLT1, VEGFA | KDR 4/4885EGFR 94/4885FGFR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.